Skip to main
COCH
COCH logo

COCH Stock Forecast & Price Target

COCH Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Envoy Medical Inc. is well-positioned for growth due to its attractive current valuation and significant upside potential as reflected in its NPV analysis, which indicates a positive outlook for investors. The company has substantial expansion opportunities, given that approximately 50% of the hearing device market is international, allowing for increased market penetration and revenue generation. Additionally, the recent FDA approval for the Acclaim CI's IDE application paves the way for future clinical testing, potentially enhancing the company's product offerings and bolstering its competitive edge in the hearing health sector.

Bears say

Envoy Medical Inc. reported a net loss of $6.2 million, translating to an earnings per share (EPS) of $(0.29), which is slightly better than internal estimates but indicates a continuing trend of financial losses. The company's financial outlook is clouded by multiple risks, including balance sheet and liquidity concerns, reliance on the success of clinical trials, and challenges related to regulatory approvals and market commercialization. Furthermore, external factors such as competition, changing macroeconomic conditions, and investor sentiment surrounding biotech investments further exacerbate the company's uncertain financial future.

COCH has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Envoy Medical Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Envoy Medical Inc (COCH) Forecast

Analysts have given COCH a Strong Buy based on their latest research and market trends.

According to 1 analysts, COCH has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Envoy Medical Inc (COCH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.